The contribution of Organic Anion Transporters OAT1 and OAT3 to the renal uptake of rosuvastatin

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 3, 2007, Pages 1221-1227

  Windass, A S ^a   Lowes, S ^a   Wang, Y ^b   Brown, Colin D A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; ESTRONE SULFATE; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; PENICILLIN G; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BASOLATERAL MEMBRANE; CONTROLLED STUDY; DRUG EFFECT; DRUG UPTAKE; FEMALE; KIDNEY PARENCHYMA; KIDNEY TUBULE ABSORPTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TISSUE SECTION;

ANIMALS; ESTRONE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; OOCYTES; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; POLYCYCLIC HYDROCARBONS, AROMATIC; PYRIMIDINES; RATS; SULFONAMIDES; TRANSFECTION; XENOPUS;

EID: 34548060345     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.125831     Document Type: Article

References (24)

1. Bleasby K, Hall LA, Perry JL, Mohrenweiser HW, and Pritchard JB (2005) Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6). J Pharmacol Exp Ther 314:923-931.
2. Cha SH, Sekine T, Fukushima J, Kanai Y, Kobayashi Y, Goya T, and Endou H (2001) Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59:1277-1286.
3. Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, and Sweet DH (1999) The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 56:570-580.
4. Dantzler WH (2006) The use of mammalian cortical kidney slices for the study of tubule secretion: a pioneering step toward understanding organic anion transport. Am J Physiol Renal Physiol 290:F1-F3.
5. Deguchi T, Kusuhara H, Takadate A, Endou H, Otagiri M, and Sugiyama Y (2004) Characterization of uremic toxin transport by organic anion transporters in the kidney. Kidney Int 65:162-174.
6. Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, and Sugiyama Y (2002) Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther 300:746-753.
7. Hatanaka T (2000) Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet 39:397-412.
8. Hosoyamada M, Sekine T, Kanai Y, and Endou H (1999) Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol 276:F122-F128.
9. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, and Schneck D (2005) Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78:330-341.
10. Martin PD, Warwick MJ, Dane AL, Brindley C, and Short T (2003) Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 25:2553-2563.
11. Olsson AG (2001) Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin rosuvastatin. Am J Cardiol 87:33B-36B.
12. Race JE, Grass SM, Williams WJ, and Holtzman EJ (1999) Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun 255:508-514.
13. Reinoso RF, Sanchez Navarro A, Garcia MJ, and Prous JR (2001) Pharmacokinetic interactions of statins. Methods Find Exp Clin Pharmacol 23:541-566.
14. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CDA, Windass AS, and Raza A (2004) The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75:455-463.
15. Sekine T, Miyazaki H, and Endou H (2006) Molecular physiology of renal organic anion transporters. Am J Physiol Renal Physiol 290:F251-F261.
16. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, and Endou H (1997) Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem 272:18526-18529.
17. Shitara Y and Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112:71-105.
18. Sweet DH (2005) Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicol Appl Pharmacol 204:198-215.
19. Sweet DH, Wolff NA, and Pritchard JB (1997) Expression cloning and characterization of ROAT1: the basolateral organic anion transporter in rat kidney. J Biol Chem 272:30088-30095.
20. Takeda M, Noshiro R, Onozato ML, Tojo A, Hasannejad H, Huang X, Narikawa S, and Endou H (2004) Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. Eur J Pharmacol 483:133-138.
21. van Montfoort JE, Hagenbuch B, Groothuis GMM, Koepsell H, Meier PJ, and Meijer DKF (2003) Drug uptake systems in liver and kidney. Curr Drug Metab 4:185-211.
22. Vickers A, Duncan CA, Chen I, Rosegay A, and Duggan DE (1990) Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 18:138-145.
23. White CM (2002) A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 42:963-970.
24. Wright SH and Dantzler WH (2004) Molecular and cellular physiology of renal organic cation and anion transport. Physiol Rev 84:987-1049.